Answers are grounded in this paper and cite their sources.
Lipopolysaccharide (LPS), a major component of the Gram-negative bacterial outer membrane, is a potent endotoxin responsible for triggering severe host immune responses and sepsis. Understanding the atomic-level mechanisms governing how antimicrobial peptides (AMPs) recognize and neutralize LPS is essential for designing effective anti-endotoxin therapeutics. Here, we present an in silico investigation of the single-molecule interaction between Escherichia coli O111:B4 LPS and the cationic antimicrobial peptide GL13K, alongside two single-point mutants at position 9 (GL13KS9A and GL13KS9T), using all-atom molecular dynamics and umbrella sampling simulations. Consistent with experimental trends, mutating SER9 into alanine significantly alters peptide binding affinity to LPS. Surpisingly, removal of the polar character of serine leads to substantial changes in the interaction of the N-terminus with LPS via the loss of hydrogen bonding to stabilize a hook shape at the C-terminal end. In specific, while wild-type GL13K exhibits the strongest unbinding free-energy barrier, the S9A substitution changes the conformational landscape in such a way as to redirect the peptide's N-terminus from lipid A toward the core oligosaccharide and substantially reduces the unbinding barrier, whereas S9T maintains an similar affinity. Our work demonstrates the effects of distal mutations even in peptides on their binding and lays important groundwork for the development of peptide-based LPS inhibitors.
No takes yet. Share an insight, caveat, or question.
Hamidabad et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: